查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1857532

癌症基因治疗市场按载体类型、治疗类型、适应症、分期和最终用户划分－2025-2032年全球预测

Cancer Gene Therapy Market by Vector Type, Therapy Type, Indication, Stage, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，癌症基因治疗市场规模将达到 118.1 亿美元，复合年增长率为 19.94%。

主要市场统计数据
基准年 2024 27.5亿美元
预计年份：2025年 33亿美元
预测年份：2032年 118.1亿美元
复合年增长率 (%) 19.94%

透过整合科学进步、递送创新和切实可行的转化策略，加速临床可行的癌症基因疗法的出现。

癌症基因治疗正处于曲折点，数十年的基础科学研究正与实际临床应用和工业化生产融合。近年来，载体工程、递送方式和分子标靶的进步，已使许多概念从实验室原理验证阶段迈向人体试验阶段，并在某些情况下最终应用于临床。同时，基因组分析、患者分层和伴随诊断技术的改进，使得治疗构建体能够更精准地与生物学定义的特定人群相匹配，从而提高临床效用的可能性，并为研发优先级的确定提供依据。

新的技术突破、监管调整和不断发展的商业模式正在重塑治疗方法的设计、生产和患者获取途径。

近年来，癌症基因治疗领域发生了变革性的变化，这主要源于技术、监管和商业动态的交汇，这些因素显着改变了计画的风险状况和市场准入的考虑。在技​​术方面，载体设计的改进，包括优化精神趋向性和降低免疫抗原性，以及非病毒递送平台（例如脂质奈米颗粒）的创新，正在拓展可适应症和患者群体的范围。同时，生产技术的规模化生产也日趋成熟可靠，从而能够生产出更高品质、更高产量且分析控制更稳定的载体。

评估美国关税政策变化对原材料采购、供应链韧性和跨境临床营运的营运和策略影响

影响跨境贸易的政策介入措施，例如关税调整及相关海关措施，正开始对生技药品和先进治疗材料的采购、供应链发展产生影响。关税结构的变化可能会增加进口原料的成本，例如特殊脂质、质体DNA生产试剂、病毒载体原料和一次性生产组件。这些增加的投入成本可能转化为早期研发公司和受託製造厂商营运预算的增加，进而影响供应商整合、近岸采购和垂直整合等方面的决策。

临床和商业细分市场的进一步划分揭示了载体选择、治疗方式、适应症复杂性、研发阶段和最终用户如何影响策略重点。

在一个细緻的细分框架阐明了载体类型、治疗方法、适应症、研发阶段和最终用户等不同维度下，临床前景和商业性可行性的交汇点。按载体类型分析，非病毒载体和病毒载体之间的差异决定了研发重点。非病毒载体包括脂质奈米颗粒、物理方法和聚合物奈米颗粒，其优点在于生产规模化和降低长期免疫抗原性风险。另一方面，病毒载体包括腺结合病毒、腺病毒、慢病毒和逆转录病毒平台，其优势在于转基因表达持久且可进行细胞特异性递送，但需要专门的生产过程和安全性监测。此外，治疗方法类型区分了体外和体内方法。体外方法利用自体或异体细胞工程工作流程，而体内方法则强调直接向组织进行全身性或局部给药。

美洲、欧洲、中东和非洲以及亚太地区的竞争格局和病患准入情况将塑造差异化的研发和商业化策略。

区域动态至关重要，因为不同地区的法律规范、报销环境、生产能力和患者获取模式存在显着差异。在美洲，成熟的监管管道、完善的商业性报销机制和专注的生产生态系统支持加速临床开发和商业化，但开发需要强有力的卫生经济学证据和支付方的积极参与。相反，欧洲、中东和非洲的情况则截然不同。儘管欧盟各司法管辖区提供协调一致的监管机制，但在报销时间表和卫生技术评估预期方面仍存在差异。同时，中东和非洲的某些市场为建立策略伙伴关係关係以扩大患者获取途径提供了机会，但这需要製定个人化的监管和分销策略。

整合平台差异化、生产规模和合作伙伴关係模式的企业策略将决定从临床前景到商业性影响的进程。

公司层面的癌症基因治疗发展轨迹受三个相互依存的因素驱动：科学研究平台深度、生产和规模化能力，以及在伙伴关係与许可方面的策略姿态。拥有专有载体工程和递送平台的公司可以获得差异化的临床优势，但将这些优势转化为临床验证需要透过稳健的临床前模型和优化的CMC（化学、製造和控制）管道来谨慎地降低风险。同时，那些确保可靠生产能力的公司——无论是内部投资还是长期製造外包伙伴关係——都能降低执行风险，并确保关键测试和商业化上市的按时完成。因此，生产规模和品管方面的专业知识往往是至关重要的差异化因素。

生物製药领导者可采取切实可行的策略步骤，以降低技术风险、加强供应链并协调与监管机构和支付方的关係，从而加快产品上市。

产业领导者应采取多管齐下的行动计划，同时应对技术风险、供应链脆弱性、监管复杂性和支付方参与等问题。首先，应儘早优先选择载体和递送方式，并设立明确的决策节点，充分考虑可转化性、可生产性和免疫抗原性。其次，应投资于灵活的生产策略，包括与合格的製造外包合作、尽可能就近采购以及建立应急能力以降低关税和物流风险。这些措施将提高营运韧性，并加快成功专案的规模化推广。

透明且可重复的研究途径，结合一手专家访谈、二手科学综合分析和质性检验，能够得出可靠的结论。

本执行摘要的研究整合了第一手和第二手研究，以确保结论的平衡性和可重复性。第一手资料包括与临床研究人员、生产专家、监管顾问和商业行业领导者进行的结构化访谈和咨询，以了解实际营运限制、临床设计偏好和支付方观点。这些讨论指导了对载体类型、给药方法和临床策略之间技术权衡的解读，并有助于检验在生产规模化和合作活动中观察到的趋势。

整合临床、技术、监管和商业性因素，帮助相关人员了解不断发展的基因治疗肿瘤生态系统。

总而言之，癌症基因疗法正从以探索为主的领域转向以转化准确性、生产准备度和商业性敏锐度为成功标准的关键领域转变。载体和递送技术的创新正在拓展治疗范围，而临床和监管方面的经验则不断完善专案设计和病患选择。同时，供应链的考量和政策的转变正在影响营运决策，迫使企业将采购、生产和物流与策略发展计画相协调。因此，研发、生产、监管和商业团队之间的跨部门整合对于降低研发管线风险和加速患者获得治疗至关重要。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 一种基于 CRISPR 的多重基因编辑策略，用于提高 CAR-T 细胞在固体癌治疗中的持久性
  • 用于体内标靶递送治疗基因至肿瘤组织的奈米结构脂质奈米颗粒载体
  • 开发表达免疫调节细胞激素的溶瘤病毒载体以增强肿瘤清除率
  • 将人工智慧驱动的生物资讯学应用于基因治疗疫苗设计中的个人化新抗原识别
  • 自动化封闭式生产平台的出现将加速病毒基因治疗载体的GMP生产
  • 生物技术创新者与合约研发生产机构（CDMO）的策略联盟简化了癌症基因疗法的临床应用
  • 扩大监管框架，以支持新型基因疗法肿瘤治疗的加速核准管道
  • 多重碱基编辑技术在固体癌原位矫正致癌点突变的进展
  • 透过开发结合基因疗法和免疫查核点抑制剂的多模态联合治疗来克服肿瘤抗药性机制

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按载体类型分類的癌症基因治疗市场

  • 非病毒载体
    • 脂质奈米颗粒
    • 物理方法
    • 聚合物奈米粒子
  • 病毒载体
    • 腺相关
    • 腺病毒
    • 慢病毒
    • 逆转录病毒

第九章 癌症基因治疗市场（依治疗类型划分）

  • 体外
  • 体内

第十章 依适应症分類的癌症基因治疗市场

  • 血癌
    • 白血病
    • 淋巴瘤
    • 多发性骨髓瘤
  • 固体癌
    • 乳癌
    • 大肠直肠癌
    • 肺癌
    • 摄护腺癌

第十一章 癌症基因治疗市场（按阶段划分）

  • 实验室测试
    • 阶段
    • 第二阶段
    • 第三阶段
  • 商业的
  • 临床前试验

第十二章 依最终用户分類的癌症基因治疗市场

  • 医院诊所
  • 肿瘤中心
  • 研究所

第十三章 各地区癌症基因治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 癌症基因治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国癌症基因治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Gilead Sciences, Inc.
    • Novartis AG
    • Bristol-Myers Squibb Company
    • Amgen Inc.
    • bluebird bio, Inc.
    • Adaptimmune Therapeutics plc
    • Cellectis SA
    • uniQure NV
    • Transgene SA
    • Sorrento Therapeutics, Inc.
Product Code: MRR-B1685377A6FA

The Cancer Gene Therapy Market is projected to grow by USD 11.81 billion at a CAGR of 19.94% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.75 billion
Estimated Year [2025] USD 3.30 billion
Forecast Year [2032] USD 11.81 billion
CAGR (%) 19.94%

Catalyzing the emergence of clinically viable cancer gene therapies through integrated scientific advances, delivery innovations, and pragmatic translational strategies

Cancer gene therapy sits at an inflection point where decades of foundational science are converging with pragmatic clinical execution and industrial-scale manufacturing. Over recent years, advances in vector engineering, delivery modalities, and molecular targeting have transitioned many concepts from laboratory proof-of-principle to human testing, and in selected cases to clinical adoption. Simultaneously, improvements in genomic profiling, patient stratification, and companion diagnostics are enabling more precise matching of therapeutic constructs to biologically defined populations, thereby improving the probability of clinical benefit and informing development prioritization.

Consequently, stakeholders across research, development, manufacturing, and commercialization must approach gene therapy with a dual lens: one that appreciates the unique scientific demands of nucleic acid delivery and one that anticipates regulatory, reimbursement, and operational realities. As a result, strategic planning today requires integrated thinking about vector selection, manufacturing capacity, clinical trial design, and payer engagement. By aligning translational science with practical implementation pathways, organizations can shorten the path from target validation to patient access while managing technical risk and capital deployment.

Emerging technological breakthroughs, regulatory recalibrations, and evolving commercial models are reshaping therapeutic design, manufacturing, and patient access pathways

Recent transformative shifts in the cancer gene therapy landscape are driven by intersecting technological, regulatory, and commercial dynamics that materially alter program risk profiles and go-to-market calculus. On the technology front, improvements in vector design, including optimized tropism and reduced immunogenicity, as well as innovations in nonviral delivery platforms such as lipid nanoparticles, have expanded the range of feasible indications and patient populations. At the same time, manufacturing technologies are scaling more reliably, enabling higher-quality vectors at improved yields and with more consistent analytical control, which reduces batch variability and supports multi-site clinical development.

From a regulatory and policy perspective, agencies are refining guidance to better address the unique safety and quality considerations of gene therapies, while payers and health technology assessment bodies are experimenting with value-based contracting and outcomes-linked reimbursement. Collectively, these shifts are lowering certain barriers to entry and increasing the strategic value of partnerships between small innovators and established manufacturers. Consequently, organizations that can combine deep translational expertise with robust manufacturing partnerships and proactive payer engagement will be best positioned to convert scientific promise into sustainable clinical impact.

Assessing the operational and strategic implications of United States tariff policy changes on raw material sourcing, supply chain resilience, and cross-border clinical operations

Policy interventions affecting cross-border trade, including tariff revisions and related customs measures, have begun to influence procurement, sourcing, and supply chain architecture for biologics and advanced therapy materials. Changes in tariff structures can increase the cost of imported raw materials such as specialty lipids, plasmid DNA production reagents, viral vector inputs, and single-use manufacturing components. These incremental input costs translate into higher operational budgets for both early-stage developers and contract manufacturing organizations, which in turn may affect decisions about supplier consolidation, near-sourcing, or vertical integration.

Moreover, tariffs exert secondary effects on logistics and inventory strategies. To mitigate exposure to unpredictable policy shifts, companies are increasingly evaluating dual-sourcing strategies, regionalized inventories, and investments in local manufacturing capability. Consequently, clinical programs with geographically distributed trial sites must balance the desire for global patient enrollment against the complexity and cost of cross-border product shipments and import/export compliance. Over time, these structural responses can reshape partnership models and influence where organizations choose to site critical manufacturing and fill-finish operations, thereby altering the economics and speed of clinical and commercial deployment.

Disaggregated clinical and commercial segmentation reveals how vector choice, therapeutic modality, indication complexity, development stage, and end users shape strategic priorities

A nuanced segmentation framework clarifies where clinical promise intersects with commercial practicality across vector modalities, therapeutic approaches, indications, development stages, and end users. When analyzed by vector type, distinctions between nonviral and viral vectors shape R&D priorities: nonviral vectors encompass lipid nanoparticles, physical methods, and polymeric nanoparticles, offering advantages in manufacturing scalability and reduced long-term immunogenicity concerns, while viral vectors include adeno-associated, adenoviral, lentiviral, and retroviral platforms that provide durable transgene expression and cell-specific delivery advantages but demand specialized manufacturing and safety monitoring. Complementing this, therapy type differentiates ex vivo and in vivo approaches, with ex vivo modalities leveraging autologous or allogeneic cell manipulation workflows and in vivo strategies emphasizing direct systemic or localized delivery to tissues.

Indication segmentation further refines clinical strategy. Hematological cancers, including leukemia, lymphoma, and myeloma, have been fertile ground for adoptive cell therapies and targeted gene modifications because of accessible cell sources and well-characterized biomarkers, whereas solid tumors such as breast cancer, colorectal cancer, lung cancer, and prostate cancer present delivery barriers and immunosuppressive microenvironments that necessitate novel targeting and combination approaches. Stage segmentation is equally consequential: preclinical work informs vector selection and nonclinical safety profiling, clinical trials span Phase I, Phase II, and Phase III with escalating complexity in endpoint selection and operational scale, and commercial programs require robust quality systems and distribution networks. Finally, end users such as hospitals and clinics, specialized oncology centers, and research laboratories impose distinct demands on product presentation, cold chain logistics, training requirements, and reimbursement interactions. Taken together, these interlocking segmentation dimensions determine technology risk, capital intensity, partner selection, and commercialization pathways.

Regional competitive contours and patient access narratives across the Americas, Europe Middle East & Africa, and Asia-Pacific shape differentiated development and commercialization strategies

Regional dynamics matter because regulatory frameworks, reimbursement environments, manufacturing capacity, and patient access models differ substantially across geographies. In the Americas, mature regulatory pathways, established commercial reimbursement mechanisms, and concentrated manufacturing ecosystems support accelerated clinical development and commercialization, but market access requires robust health economic evidence and payer engagement. Conversely, Europe, Middle East & Africa exhibit heterogeneity: EU jurisdictions offer coordinated regulatory mechanisms yet diverge on reimbursement timelines and HTA expectations, while certain markets in the Middle East and Africa present opportunities for strategic partnerships to expand access but necessitate tailored regulatory and distribution strategies.

In the Asia-Pacific region, rapid investments in local manufacturing, rising clinical trial activity, and growing government support for biotechnology create fertile conditions for clinical translation and regional supply chains. However, differences in regulatory harmonization, patient population genetics, and healthcare infrastructure mean that go-to-market plans must be regionally adapted. Therefore, organizations should prioritize regulatory intelligence, localized clinical pathways, and supply chain resiliency when establishing presence across the Americas, Europe, Middle East & Africa, and Asia-Pacific to ensure that development timelines and commercial rollouts remain aligned with regional realities.

Company strategies that integrate platform differentiation, manufacturing scale, and collaborative partnership models determine who advances from clinical promise to commercial impact

Company-level trajectories in cancer gene therapy are driven by three interdependent factors: the depth of scientific platform, manufacturing and scale capabilities, and the strategic posture toward partnerships and licensing. Organizations with proprietary vector engineering or delivery platforms can capture differentiated clinical advantages, but translating those advantages into clinical proof requires careful de-risking through robust preclinical models and optimized CMC pathways. In parallel, companies that secure reliable manufacturing capacity-either through in-house investment or long-term contract manufacturing partnerships-reduce execution risk and maintain timelines for pivotal studies and commercial launches. Thus, manufacturing footprint and quality control expertise often become decisive differentiators.

Furthermore, firms adopting collaborative business models that combine early-stage innovation with established commercial or manufacturing partners tend to accelerate patient access while preserving upside through milestone and royalty structures. Strategic alliances that align clinical development plans, regulatory submission strategies, and market access evidence generation help firms navigate HTA negotiations and payer dialogues. Ultimately, the most successful companies will be those that integrate scientific differentiation with pragmatic manufacturing strategies and thoughtful commercial partnerships to move therapies from proof-of-concept to reliable patient delivery.

Actionable strategic measures for biopharma leaders to reduce technical risk, reinforce supply chains, and align regulatory and payer engagement for accelerated access

Industry leaders should adopt a multi-pronged action plan that addresses technical risk, supply chain fragility, regulatory complexity, and payer engagement concurrently. First, prioritize vector and delivery selection early with clear decision gates that weigh translatability, manufacturability, and immunogenicity; this reduces downstream attrition and focuses capital on the most viable constructs. Second, invest in flexible manufacturing strategies that include qualified contract manufacturing partnerships, near-sourcing where feasible, and contingency capacity to mitigate tariff and logistics risks. These moves improve operational resilience and accelerate the ability to scale successful programs.

Third, engage regulators and payers proactively to align on evidentiary needs, safety monitoring frameworks, and value demonstration pathways; early alignment reduces the risk of late-stage surprises and facilitates smoother reimbursement discussions. Fourth, design clinical programs that incorporate robust biomarker strategies and adaptive elements to enhance patient selection and endpoint sensitivity. Finally, pursue partnerships that augment internal capabilities-whether for manufacturing, regulatory expertise, or commercial infrastructure-so that scientific innovators can leverage complementary strengths and accelerate patient access. Taken together, these actions create a pragmatic roadmap for converting scientific innovation into durable clinical and commercial outcomes.

A transparent and reproducible research approach combining primary expert interviews, secondary scientific synthesis, and qualitative validation to support robust conclusions

The research underpinning this executive summary integrated primary stakeholder engagement with systematic secondary synthesis to ensure balanced, reproducible conclusions. Primary inputs included structured interviews and consultations with clinical investigators, manufacturing experts, regulatory advisors, and commercial leaders to capture real-world operational constraints, clinical design preferences, and payer perspectives. These discussions informed the interpretation of technical tradeoffs between vector types, delivery methods, and clinical strategies, and helped validate observed trends in manufacturing scale-up and partnership activity.

Secondary research involved a comprehensive review of peer-reviewed literature, regulatory guidance documents, conference proceedings, and company disclosures to map technological developments and regulatory evolution. Throughout the process, qualitative validation steps such as cross-checking assertions with multiple independent experts and reconciling divergent viewpoints were applied to reduce bias. Finally, findings were synthesized to highlight strategic implications rather than to produce proprietary market metrics, ensuring the analysis emphasizes actionable intelligence for decision-makers while remaining transparent about methodology and evidence sources.

Synthesis of clinical, technical, regulatory, and commercial considerations to guide stakeholders through the evolving gene therapy oncology ecosystem

In summary, cancer gene therapy is transitioning from a predominantly exploratory field to one in which translational fidelity, manufacturing readiness, and commercial foresight jointly determine success. Vector and delivery innovations broaden the therapeutic scope, while clinical and regulatory learnings refine program design and patient selection. Meanwhile, supply chain considerations and policy shifts influence operational choices, compelling organizations to align sourcing, manufacturing, and logistics with strategic development plans. As a result, cross-functional integration across R&D, manufacturing, regulatory, and commercial teams is essential to de-risk pipelines and accelerate patient access.

Looking ahead, the ecosystem will reward entities that combine rigorous translational science with disciplined program management and strategic partnerships. By focusing on modular manufacturing investments, proactive regulatory engagement, and evidence generation that resonates with payers, developers can improve the predictability of development pathways and enhance the likelihood of sustainable clinical impact. Ultimately, careful orchestration of technical, operational, and commercial activities will determine which therapies achieve broad patient adoption and which programs stall despite promising biology.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. CRISPR-based multiplexed gene editing strategies refining CAR-T cell persistence in solid tumor treatments
  • 5.2. Nanoformulated lipid nanoparticle carriers enabling in vivo targeted delivery of therapeutic genes to tumor tissue
  • 5.3. Development of oncolytic viral vectors expressing immunomodulatory cytokines to enhance tumor eradication
  • 5.4. Integration of AI-driven bioinformatics for personalized neoantigen identification in gene therapy vaccine design
  • 5.5. Emergence of automated closed-system manufacturing platforms accelerating GMP production of viral gene therapy vectors
  • 5.6. Strategic alliances between biotech innovators and CDMOs streamlining clinical translation of cancer gene therapies
  • 5.7. Expanding regulatory frameworks supporting expedited approval pathways for novel gene therapy oncology treatments
  • 5.8. Advances in multiplexed base editing techniques to correct oncogenic point mutations in solid tumor cells in situ
  • 5.9. Deploying multi-modal combination therapies coupling gene therapy with immune checkpoint blockade to overcome tumor resistance mechanisms

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Gene Therapy Market, by Vector Type

  • 8.1. Nonviral Vectors
    • 8.1.1. Lipid Nanoparticles
    • 8.1.2. Physical Methods
    • 8.1.3. Polymeric Nanoparticles
  • 8.2. Viral Vectors
    • 8.2.1. Adeno-Associated
    • 8.2.2. Adenoviral
    • 8.2.3. Lentiviral
    • 8.2.4. Retroviral

9. Cancer Gene Therapy Market, by Therapy Type

  • 9.1. Ex Vivo
  • 9.2. In Vivo

10. Cancer Gene Therapy Market, by Indication

  • 10.1. Hematological Cancers
    • 10.1.1. Leukemia
    • 10.1.2. Lymphoma
    • 10.1.3. Myeloma
  • 10.2. Solid Tumors
    • 10.2.1. Breast Cancer
    • 10.2.2. Colorectal Cancer
    • 10.2.3. Lung Cancer
    • 10.2.4. Prostate Cancer

11. Cancer Gene Therapy Market, by Stage

  • 11.1. Clinical Trials
    • 11.1.1. Phase I
    • 11.1.2. Phase II
    • 11.1.3. Phase III
  • 11.2. Commercial
  • 11.3. Preclinical

12. Cancer Gene Therapy Market, by End User

  • 12.1. Hospitals And Clinics
  • 12.2. Oncology Centers
  • 12.3. Research Laboratories

13. Cancer Gene Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cancer Gene Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Gene Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Gilead Sciences, Inc.
    • 16.3.2. Novartis AG
    • 16.3.3. Bristol-Myers Squibb Company
    • 16.3.4. Amgen Inc.
    • 16.3.5. bluebird bio, Inc.
    • 16.3.6. Adaptimmune Therapeutics plc
    • 16.3.7. Cellectis S.A.
    • 16.3.8. uniQure N.V.
    • 16.3.9. Transgene SA
    • 16.3.10. Sorrento Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CANCER GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CANCER GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANCER GENE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 325. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 326. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2